UK markets closed

Santhera Pharmaceuticals Holding AG (SPHDF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
1.40000.0000 (0.00%)
At close: 10:59AM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.4000
Open1.4000
Bid0.0000 x 0
Ask0.0000 x 0
Day's range1.4000 - 1.4000
52-week range1.3700 - 5.6100
Volume12,500
Avg. volume1,182
Market cap24.534M
Beta (5Y monthly)1.26
PE ratio (TTM)N/A
EPS (TTM)-3.2620
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Santhera Provides Corporate Update and Calls Extraordinary General Meeting to Seek Approval for Further Financings

    Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, November 24, 2021 – Santhera Pharmaceuticals (SIX: SANN) provides an update on its activities and is calling an Extraordinary General Meeting (EGM), which will be held on December 15, 2021, at 10:30 hrs at the domicile of the Company. At the EGM, Santhera seeks authorization for additional funding to enable continued pipeline development and preparations for the commercialization of vamorolone. Corporate Update In the course of th

  • Globe Newswire

    Santhera and ReveraGen Announce Positive Topline Results with Vamorolone after Completion of the VISION-DMD Study

    Ad hoc announcement pursuant to Art. 53 LR Vamorolone given throughout the study showed sustained efficacy across multiple endpoints over 48 weeks and the good safety and tolerability profile was confirmedSwitching from prednisone to vamorolone after week 24 maintained efficacy and improved on multiple safety parameters including restoration of growth trajectory and reduction of behavioral changes up to week 48Switching from placebo to vamorolone after week 24 resulted in an improvement of multi

  • Globe Newswire

    Santhera and ReveraGen Announce Successful FDA Pre-NDA Meeting for Vamorolone in Duchenne Muscular Dystrophy

    Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, and Rockville, MD, USA, November 17, 2021 –Santhera Pharmaceuticals (SIX: SANN) and ReveraGen Biopharma (US: private) announce the successful completion of a first pre-NDA meeting with the U.S. Food and Drug Administration (FDA) for vamorolone for the treatment of Duchenne muscular dystrophy (DMD). The FDA considered both the proposed clinical efficacy and safety data sufficient for an NDA filing. Based on the Fast Track Designati